GSD NovaType Detect + Select SARS-CoV-2 (1x96)

GSD NovaType Detect + Select SARS-CoV-2 (1x96)

RSV A, RSV B RT-PCR

RSV A, RSV B RT-PCR

Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR

Respiratory diseases caused by SARS-CoV-2, RSV, and Influenza virus have similar first clinical symptoms, and accurate identification is crucial for better patient care.

The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay allows to differentiate in a single reaction between Influenza A and B, and simultaneously detects two independent gene targets in SARS-CoV-2 (N-gene + RdRP-gene).

Not available in the US.

Respiratory diseases caused by SARS-CoV-2, RSV, and Influenza virus have similar first clinical symptoms, and accurate identification is crucial for better patient care.

The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay allows to differentiate in a single reaction between Influenza A and B, and simultaneously detects two independent gene targets in SARS-CoV-2 (N-gene + RdRP-gene)1.

In addition, the RSV A, RSV B RT-PCR assay is capable of differentiating between respiratory syncytial virus A and B.

  •   • Validated sample material: nasopharyngeal wash/swab, oropharyngeal swab, nasal wash/swab
  •   • RNaseP used as internal control for sample quality, RNA extraction, and detection of inhibitors
  •   • Fast and reliable results in approximately 1 hour
  •   • Validated thermocyclers: AriaDxTM, AriaMxTM from Agilent Technologies
  •   • Contributes to meet local regulatory requirements for pathogen testing
  •   • CE IVD marked
1 World Health Organization. (2020). Diagnostic testing for SARS-CoV-2: interim guidance, 11 September 2020. World Health Organization. https://apps.who.int/iris/handle/10665/334254.
More Information
SKU PRES6131
No. of tests 1 x 96
PCR cycler platforms AriaDxTM, AriaMxTM (Agilent Technologies)